v3.26.1
Provisions (Tables)
6 Months Ended
Jun. 30, 2026
Disclosure of other provisions [abstract]  
Summary of Changes in Current and Non-Current Provisions
Changes in the Group's current and non-current provisions were as follows:
Warranties
Employee benefits
Litigation1
Other2
Total
Balance as of January 1, 2026
162,093 
6,416 
28,999 
56,819 
254,327 
Additions
48,715 
15,213 
— 
58,802 
122,730 
Utilization
(54,850)
(9,367)
(26,372)
(21,648)
(112,237)
Reversals
(12,318)
(108)
— 
(9,132)
(21,558)
Unwinding of discount and effect of changes in discount rate
(983)
— 
— 
— 
(983)
Effect of foreign currency exchange differences
(5,052)
(527)
— 
(895)
(6,474)
Balance as of June 30, 2026
137,605 
11,627 
2,627 
83,946 
235,805 
of which current
37,627 
11,627 
2,627 
63,432 
115,313 
of which non-current
99,978 
— 
— 
20,514 
120,492 
Balance as of January 1, 2025
128,591 
902 
27,135 
10,898 
167,526 
Additions
56,724 
5,373 
— 
31,411 
93,508 
Utilization
(29,439)
(887)
(53)
(9,951)
(40,330)
Reversals
(15,440)
(648)
(583)
(143)
(16,814)
Unwinding of discount and effect of changes in discount rate
(456)
— 
— 
— 
(456)
Effect of foreign currency exchange differences
13,367 
897 
— 
1,267 
15,531 
Balance as of June 30, 2025
153,347 
5,637 
26,499 
33,482 
218,965 
of which current
59,702 
5,637 
26,499 
22,926 
114,764 
of which non-current
93,645 
— 
— 
10,556 
104,201 
1 - In the six months ended June 30, 2026, the utilization of $26,372 was primarily related to the settlement of the Gores Guggenheim ("GGI") litigation filed in August 2023, for which Polestar was obligated to indemnify the defendants under the terms of the Business Combination Agreement. For further information of the GGI litigation, see Note 22 - Provisions from the 2025 Consolidated Financial Statements.
2 - In the six months ended June 30, 2026, the additions of $58,802 primarily relate to the U.S. Restructuring (refer to Note 1 - Overview and basis of preparation), and in the six months ended June 30, 2025, the additions of $31,411 primarily relate to provisions for restructuring initiated in 2025 (mainly the R&D and Procurement departments in the UK and manufacturing in China).